[
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-13 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement",
    "image": "https://images.financialmodelingprep.com/news/lilly-confirms-date-and-conference-call-for-firstquarter-2023-20230413.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",
    "url": "https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-first-quarter-2023-financial-results-announcement-301794926.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-13T10:00:00-04:00",
    "date_et": "2023-04-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-13 16:30:00",
    "publisher": "PRNewsWire",
    "title": "U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab",
    "image": "https://images.financialmodelingprep.com/news/us-food-and-drug-administration-issues-complete-response-letter-20230413.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , April 13, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the mirikizumab biologic license application (BLA) for the treatment of ulcerative colitis (UC). In the letter, the FDA cited issues related to the proposed manufacturing of mirikizumab, with no concerns about the clinical data package, safety, or label for the medicine.",
    "url": "https://www.prnewswire.com/news-releases/us-food-and-drug-administration-issues-complete-response-letter-for-mirikizumab-301796847.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-13T16:30:00-04:00",
    "date_et": "2023-04-13"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-14 12:55:43",
    "publisher": "Zacks Investment Research",
    "title": "Lilly's (LLY) Ulcerative Colitis Candidate Gets CRL from FDA",
    "image": "https://images.financialmodelingprep.com/news/lillys-lly-ulcerative-colitis-candidate-gets-crl-from-fda-20230414.jpg",
    "site": "zacks.com",
    "text": "The FDA rejects Eli Lilly's (LLY) regulatory filing seeking approval for mirikizumab to treat ulcerative colitis indication, citing issues related to the drug's proposed manufacturing.",
    "url": "https://www.zacks.com/stock/news/2079035/lilly-s-lly-ulcerative-colitis-candidate-gets-crl-from-fda",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-14T12:55:43-04:00",
    "date_et": "2023-04-14"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-16 08:30:06",
    "publisher": "InvestorPlace",
    "title": "Get In Now. 3 Stocks That Are Set to Soar.",
    "image": "https://images.financialmodelingprep.com/news/get-in-now-3-stocks-that-are-set-to-20230416.jpg",
    "site": "investorplace.com",
    "text": "As the market shows some stability, investors are looking for stocks to buy for the long term. Some great stocks remain undervalued and look like bargains at their current prices, but for how long?",
    "url": "https://investorplace.com/2023/04/3-stocks-to-buy-stocks-that-are-set-to-soar/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-16T08:30:06-04:00",
    "date_et": "2023-04-16"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-17 11:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities",
    "image": "https://images.financialmodelingprep.com/news/lilly-to-make-recordbreaking-investment-in-indiana-manufacturing-facilities-20230417.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS, April 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will invest an additional $1.6 billion and add another 200 new jobs at its two new manufacturing sites within LEAP Innovation Park in Boone County, bringing the company's total commitment to $3.7 billion and up to 700 new jobs. The company also today committed $15 million over five years to the Ivy Tech Foundation to fund up to 1,000 scholarships for individuals interested in pursuing careers in pharmaceutical manufacturing.",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-make-record-breaking-investment-in-indiana-manufacturing-facilities-301798439.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-17T11:00:00-04:00",
    "date_et": "2023-04-17"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-17 12:56:36",
    "publisher": "Zacks Investment Research",
    "title": "SNY vs. LLY: Which Stock Is the Better Value Option?",
    "image": "https://images.financialmodelingprep.com/news/sny-vs-lly-which-stock-is-the-better-value-20230417.jpg",
    "site": "zacks.com",
    "text": "Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?",
    "url": "https://www.zacks.com/stock/news/2079793/sny-vs-lly-which-stock-is-the-better-value-option",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-17T12:56:36-04:00",
    "date_et": "2023-04-17"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-20 08:45:00",
    "publisher": "The Motley Fool",
    "title": "Is Eli Lilly Stock a Buy Now?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-stock-a-buy-now-20230420.jpg",
    "site": "fool.com",
    "text": "Eli Lilly has faced a series of issues over the past few months. But the drugmaker's pipeline still looks promising.",
    "url": "https://www.fool.com/investing/2023/04/20/is-eli-lilly-stock-a-buy-now/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-20T08:45:00-04:00",
    "date_et": "2023-04-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-20 10:23:00",
    "publisher": "The Motley Fool",
    "title": "Investing Your Tax Refund? These 2 Stocks Can Make the Most of Your Money",
    "image": "https://images.financialmodelingprep.com/news/investing-your-tax-refund-these-2-stocks-can-make-20230420.jpg",
    "site": "fool.com",
    "text": "Eli Lilly and Apple are cash-rich businesses that can afford to pay dividends and invest in the future. Mounjaro is a weight-loss treatment that could bring in tens of billions in revenue for Eli Lilly.",
    "url": "https://www.fool.com/investing/2023/04/20/investing-your-tax-refund-these-2-stocks-can-make/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-20T10:23:00-04:00",
    "date_et": "2023-04-20"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-21 10:41:40",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-a-trending-stock-20230421.jpg",
    "site": "zacks.com",
    "text": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://www.zacks.com/stock/news/2082658/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-21T10:41:40-04:00",
    "date_et": "2023-04-21"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-22 06:18:00",
    "publisher": "The Motley Fool",
    "title": "3 Stocks With Huge Catalysts on the Way",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-with-huge-catalysts-on-the-way-20230422.jpg",
    "site": "fool.com",
    "text": "Axsome Therapeutics has several major milestones around the corner. CRISPR Therapeutics could soon win approvals for its first product.",
    "url": "https://www.fool.com/investing/2023/04/22/3-stocks-with-huge-catalysts-on-the-way/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-22T06:18:00-04:00",
    "date_et": "2023-04-22"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-24 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly to Divest BAQSIMI to Amphastar",
    "image": "https://images.financialmodelingprep.com/news/lilly-to-divest-baqsimi-to-amphastar-20230424.jpg",
    "site": "prnewswire.com",
    "text": "Lilly focused on delivering the company's unprecedented pipeline of next-generation medicines to help patients Amphastar is the ideal company to continue Lilly's mission to help more people benefit from BAQSIMI INDIANAPOLIS and RANCHO CUCAMONGA, Calif. , April 24, 2023 /PRNewswire/ -- In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-divest-baqsimi-to-amphastar-301804855.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-24T06:45:00-04:00",
    "date_et": "2023-04-24"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-24 06:54:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly to sell hypoglycemia treatment for up to $1.1 billion in cash and milestone payments to Amphastar",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-to-sell-hypoglycemia-treatment-for-up-to-20230424.jpg",
    "site": "marketwatch.com",
    "text": "Shares of Eli Lilly & Co. LLY gained 0.5% in premarket trading Monday, after the drugmaker announced an agreement to sell its hypoglycemia treatment for people with diabetes Baqsimi to Amphastar Pharmaceuticals Inc. AMPH for up to $1.075 billion in cash and potential milestone payments. Under terms of the agreement, Amphastar will pay $500 million in cash upfront and another $125 million in cash one year after the deal closes, which is expected to occur in the third quarter of 2023.",
    "url": "https://www.marketwatch.com/story/eli-lilly-to-sell-hypoglycemia-treatment-for-up-to-1-1-billion-in-cash-and-milestone-payments-to-amphastar-81cbf58b",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-24T06:54:00-04:00",
    "date_et": "2023-04-24"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-24 12:12:15",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) to Report Q1 Earnings: Will It Beat Estimates?",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-to-report-q1-earnings-will-it-20230424.jpg",
    "site": "zacks.com",
    "text": "Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Lilly's (LLY) first-quarter sales.",
    "url": "https://www.zacks.com/stock/news/2083494/eli-lilly-lly-to-report-q1-earnings-will-it-beat-estimates",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-24T12:12:15-04:00",
    "date_et": "2023-04-24"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-24 12:30:03",
    "publisher": "Proactive Investors",
    "title": "Eli Lilly to sell Baqsimi diabetes drug to Amphastar for around $1 billion",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-to-sell-baqsimi-diabetes-drug-to-amphastar-20230424.jpg",
    "site": "proactiveinvestors.com",
    "text": "Eli Lilly and Co (NYSE:LLY) revealed that it will sell Baqsimi, its nasal treatment for severe hypoglycemia in people with diabetes, to Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for around $1 billion. The Indianapolis, Indiana-based company has signed a definitive agreement to divest Baqsimi worldwide to Amphastar for $500 million in cash at closing and an additional $125 million in cash upon the one-year anniversary of closing.",
    "url": "https://www.proactiveinvestors.com/companies/news/1013101?SNAPI",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-24T12:30:03-04:00",
    "date_et": "2023-04-24"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-24 13:13:00",
    "publisher": "Investor's Business Daily",
    "title": "Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race",
    "image": "https://images.financialmodelingprep.com/news/novo-nordisk-sinks-as-eli-lilly-plots-its-showdown-20230424.jpg",
    "site": "investors.com",
    "text": "Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment. The post Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In The Red-Hot Obesity Shot Race appeared first on Investor's Business Daily.",
    "url": "https://www.investors.com/news/technology/novo-nordisk-stock-the-obesity-treatment-showdown-is-here/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-24T13:13:00-04:00",
    "date_et": "2023-04-24"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-25 05:17:00",
    "publisher": "The Motley Fool",
    "title": "Better Buy: Novo Nordisk vs. Eli Lilly",
    "image": "https://images.financialmodelingprep.com/news/better-buy-novo-nordisk-vs-eli-lilly-20230425.jpg",
    "site": "fool.com",
    "text": "Sales of Novo Nordisk's diabetes drug and weight-management drugs are soaring. Eli Lilly's popular new diabetes drug, Mounjaro, could soon earn approval to address chronic weight management.",
    "url": "https://www.fool.com/investing/2023/04/25/better-buy-novo-nordisk-vs-eli-lilly/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-25T05:17:00-04:00",
    "date_et": "2023-04-25"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-25 10:20:00",
    "publisher": "The Motley Fool",
    "title": "2 Monster Stocks to Buy Without Any Hesitation",
    "image": "https://images.financialmodelingprep.com/news/2-monster-stocks-to-buy-without-any-hesitation-20230425.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's shares are up more than 235% over the past five years. Mounjaro is expected to be a blockbuster drug for Lilly.",
    "url": "https://www.fool.com/investing/2023/04/25/2-monster-stocks-to-buy-without-any-hesitation/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-25T10:20:00-04:00",
    "date_et": "2023-04-25"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-25 13:40:18",
    "publisher": "CNBC",
    "title": "Biogen isn't concerned about competing with Eli Lilly in the Alzheimer's drug space, CEO says",
    "image": "https://images.financialmodelingprep.com/news/biogen-isnt-concerned-about-competing-with-eli-lilly-in-20230425.jpeg",
    "site": "cnbc.com",
    "text": "Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab.",
    "url": "https://www.cnbc.com/2023/04/25/biogen-alzheimers-competition-eli-lilly.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-25T13:40:18-04:00",
    "date_et": "2023-04-25"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-26 09:54:32",
    "publisher": "Zacks Investment Research",
    "title": "Why Earnings Season Could Be Great for Eli Lilly (LLY)",
    "image": "https://images.financialmodelingprep.com/news/why-earnings-season-could-be-great-for-eli-lilly-20230426.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.",
    "url": "https://www.zacks.com/stock/news/2084816/why-earnings-season-could-be-great-for-eli-lilly-lly",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-26T09:54:32-04:00",
    "date_et": "2023-04-26"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-26 10:40:40",
    "publisher": "Zacks Investment Research",
    "title": "Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More",
    "image": "https://images.financialmodelingprep.com/news/drugbiotech-stocks-q1-earnings-due-apr-27-lly-abbv-20230426.jpg",
    "site": "zacks.com",
    "text": "Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.",
    "url": "https://www.zacks.com/stock/news/2084870/drug-biotech-stocks-q1-earnings-due-apr-27-lly-abbv-more",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-26T10:40:40-04:00",
    "date_et": "2023-04-26"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-26 13:20:54",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Is Under Pressure Today",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-under-pressure-today-20230426.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is scheduled to report 2023 Q1 earnings tomorrow. Investors seem to be concerned that Wall Street's expectations are too high.",
    "url": "https://www.fool.com/investing/2023/04/26/why-eli-lilly-stock-is-under-pressure-today/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-26T13:20:54-04:00",
    "date_et": "2023-04-26"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-26 16:30:00",
    "publisher": "Barron's",
    "title": "Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug.",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-earnings-are-soon-all-eyes-are-on-20230426.jpg",
    "site": "barrons.com",
    "text": "Expectations for first-quarter sales of its diabetes treatment, Mounjaro, are $433 million.",
    "url": "https://www.barrons.com/articles/eli-lilly-earnings-stock-price-cdbd7441",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-26T16:30:00-04:00",
    "date_et": "2023-04-26"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-26 19:46:13",
    "publisher": "Zacks Investment Research",
    "title": "Markets Continue Steady Slide; META, EBAY Beat Q1 Earnings",
    "image": "https://images.financialmodelingprep.com/news/markets-continue-steady-slide-meta-ebay-beat-q1-earnings-20230426.jpg",
    "site": "zacks.com",
    "text": "Except the Nasdaq, which snapped a two-day losing streak and was the only major index in the green all day.",
    "url": "https://www.zacks.com/stock/news/2085436/markets-continue-steady-slide-meta-ebay-beat-q1-earnings",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-26T19:46:13-04:00",
    "date_et": "2023-04-26"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 06:15:00",
    "publisher": "Barron's",
    "title": "Eli Lilly's Mounjaro Moves Toward Possible FDA Obesity Approval",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-mounjaro-moves-toward-possible-fda-obesity-approval-20230427.jpg",
    "site": "barrons.com",
    "text": "The company plans to finalize its application for FDA approval of its weight-loss drug tirzepatide, sold as Mounjaro.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-mounjaro-weight-loss-drug-trial-75e9b2eb",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T06:15:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 06:15:00",
    "publisher": "PRNewsWire",
    "title": "Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2",
    "image": "https://images.financialmodelingprep.com/news/lillys-tirzepatide-achieved-up-to-157-weight-loss-in-20230427.jpg",
    "site": "prnewswire.com",
    "text": "Participants with obesity or overweight and type 2 diabetes taking tirzepatide lost up to 34.4 lb. (15.6 kg) Lilly plans to complete rolling submission to the FDA in the coming weeks INDIANAPOLIS , April 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that tirzepatide (10 mg and 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in results from SURMOUNT-2.",
    "url": "https://www.prnewswire.com/news-releases/lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-surmount-2--301809033.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T06:15:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 06:25:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in late-stage trial",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-tirzepatide-achieved-up-to-157-weight-loss-in-20230427.jpg",
    "site": "marketwatch.com",
    "text": "Eli Lilly & Co. LLY said Thursday its tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in a late-stage trial. Participants in the phase 3 trial called Surmount-2 lost up to 34.4 pounds, the company said in a statement.",
    "url": "https://www.marketwatch.com/story/eli-lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-late-stage-trial-3d1a8d78",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T06:25:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum",
    "image": "https://images.financialmodelingprep.com/news/lilly-reports-firstquarter-2023-financial-results-highlights-continued-core-20230427.jpg",
    "site": "prnewswire.com",
    "text": "Revenue in Q1 2023 decreased 11% driven by a $1.47 billion decline in revenue from COVID-19 antibodies. Excluding COVID-19 antibodies, revenue in Q1 2023 increased 10%, driven by volume growth from Mounjaro, Trulicity, Verzenio and Jardiance.",
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-first-quarter-2023-financial-results-highlights-continued-core-business-growth-and-pipeline-momentum-301808936.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T06:45:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 07:01:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly stock up premarket as company's Q1 revenue beats and it raises guidance",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-up-premarket-as-companys-q1-revenue-20230427.jpg",
    "site": "marketwatch.com",
    "text": "Eli Lilly & Co. shares LLY rose 2% premarket Thursday, after the company posted first-quarter earnings showing a revenue beat and raised its full-year guidance. The company posted net income of $1.345 billion, or $1.49 a share, for the quarter, down from $1.903 billion, or $2.10 a share, in the year-earlier period.",
    "url": "https://www.marketwatch.com/story/eli-lilly-stock-up-premarket-as-companys-q1-revenue-beats-and-it-raises-guidance-b601b36",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T07:01:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 08:07:03",
    "publisher": "CNBC",
    "title": "Eli Lilly misses on earnings but raises full-year guidance",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-misses-on-earnings-but-raises-fullyear-guidance-20230427.jpeg",
    "site": "cnbc.com",
    "text": "The company reported adjusted earnings of $1.62, which missed analyst expectations of $1.73 for the quarter.",
    "url": "https://www.cnbc.com/2023/04/27/eli-lilly-lly-q1-earnings-2023.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T08:07:03-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 08:57:20",
    "publisher": "Investor's Business Daily",
    "title": "Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-diabetes-newcomer-mounjaro-just-blew-sales-projections-20230427.jpg",
    "site": "investors.com",
    "text": "Eli Lilly stock jumped Thursday on better-than-expected sales of diabetes newcomer, Mounjaro, helping offset a massive Covid-related decline. The post Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water appeared first on Investor's Business Daily.",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q1-2023/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T08:57:20-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 09:15:23",
    "publisher": "CNBC",
    "title": "Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-says-obesity-drug-tirzepatide-resulted-in-weight-20230427.jpeg",
    "site": "cnbc.com",
    "text": "Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.",
    "url": "https://www.cnbc.com/2023/04/27/eli-lilly-weight-loss-drug-tirzepatide-data-released.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T09:15:23-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 09:25:00",
    "publisher": "The Motley Fool",
    "title": "Is Eli Lilly Stock a Strong Buy After Q1 Earnings?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-stock-a-strong-buy-after-q1-20230427.jpg",
    "site": "fool.com",
    "text": "Shares have been on the volatile side this year due to a slew of headwinds. Over the long term, these headwinds will likely fade due to the growth potential of its rapidly emerging flagship drug, Mounjaro.",
    "url": "https://www.fool.com/investing/2023/04/27/is-eli-lilly-stock-a-strong-buy-after-q1-earnings/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T09:25:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 10:13:09",
    "publisher": "InvestorPlace",
    "title": "LLY Stock Alert: Mounjaro Takes Eli Lilly to the Next Level",
    "image": "https://images.financialmodelingprep.com/news/lly-stock-alert-mounjaro-takes-eli-lilly-to-the-20230427.png",
    "site": "investorplace.com",
    "text": "Eli Lilly (NYSE: LLY ) stock is climbing higher on Thursday thanks to a boost from Mounjaro during its earnings report for the first quarter of 2023. According to the company, diabetes drug Mounjaro strongly contributed to its revenue during the quarter.",
    "url": "https://investorplace.com/2023/04/lly-stock-alert-mounjaro-takes-eli-lilly-to-the-next-level/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T10:13:09-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 11:12:00",
    "publisher": "The Wall Street Journal",
    "title": "Obesity Drug Hype Outweighs Profit Miss at Eli Lilly",
    "image": "https://images.financialmodelingprep.com/news/obesity-drug-hype-outweighs-profit-miss-at-eli-lilly-20230427.jpg",
    "site": "wsj.com",
    "text": "Mounjaro excitement more than makes up for company's first quarter results.",
    "url": "https://www.wsj.com/articles/obesity-drug-hype-outweighs-profit-miss-at-eli-lilly-7ed3b163",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T11:12:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 11:19:42",
    "publisher": "InvestorPlace",
    "title": "Why Are Stocks Up Today?",
    "image": "https://images.financialmodelingprep.com/news/why-are-stocks-up-today-20230427.jpg",
    "site": "investorplace.com",
    "text": "Investors wondering why stocks are up today have a couple of pieces of news worth catching up on. First off, stocks are up today thanks to several large corporations releasing earnings reports.",
    "url": "https://investorplace.com/2023/04/why-are-stocks-up-today-april-27th/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T11:19:42-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 11:31:43",
    "publisher": "Proactive Investors",
    "title": "Eli Lilly stock rises after 1Q revenue beat and pipeline momentum from diabetes and weight loss drug Tirzepatide",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-rises-after-1q-revenue-beat-and-20230427.jpg",
    "site": "proactiveinvestors.com",
    "text": "Eli Lilly & Co stock climbed after the drug maker reported first-quarter earnings showing a revenue beat and raised its full-year guidance. For the quarter ended March 31, 2023, the Indianapolis-based pharma giant reported that revenue declined 11% to $6.96 billion from $7.81 billion, but was well ahead of the $6.864 billion FactSet estimate.",
    "url": "https://www.proactiveinvestors.com/companies/news/1013526?SNAPI",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T11:31:43-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 15:57:08",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly (LLY) Q1 Earnings Miss, Sales Beat, '23 View Raised",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-lly-q1-earnings-miss-sales-beat-23-20230427.jpg",
    "site": "zacks.com",
    "text": "Eli Lilly (LLY) reports mixed results for the first quarter of 2023, missing estimates for earnings while beating the same for revenues. Management raises the 2023 outlook.",
    "url": "https://www.zacks.com/stock/news/2086376/eli-lilly-lly-q1-earnings-miss-sales-beat-23-view-raised",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T15:57:08-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-27 17:49:00",
    "publisher": "The Motley Fool",
    "title": "Is Eli Lilly Stock a No-Brainer Buy After Mounjaro's Latest Big Win?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-stock-a-nobrainer-buy-after-mounjaros-20230427.jpg",
    "site": "fool.com",
    "text": "Lilly is now racing toward likely approval for Mounjaro in treating obesity after positive late-stage results. The bigger picture for the company also looks good overall.",
    "url": "https://www.fool.com/investing/2023/04/27/is-eli-lilly-stock-a-no-brainer-buy-after-mounjaro/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-27T17:49:00-04:00",
    "date_et": "2023-04-27"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-28 05:21:00",
    "publisher": "The Motley Fool",
    "title": "5 Brand-Name Safe Stocks I Wouldn't Touch With a 10-Foot Pole Right Now",
    "image": "https://images.financialmodelingprep.com/news/5-brandname-safe-stocks-i-wouldnt-touch-with-a-10foot-20230428.jpg",
    "site": "fool.com",
    "text": "The Federal Reserve is now forecasting a mild recession for later this year. When uncertainty picks up, investors typically flock to safe stocks.",
    "url": "https://www.fool.com/investing/2023/04/28/5-safe-stocks-i-wouldnt-touch-with-a-10-foot-pole/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-28T05:21:00-04:00",
    "date_et": "2023-04-28"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-28 18:11:00",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Was a Winner Today",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-was-a-winner-today-20230428.jpg",
    "site": "fool.com",
    "text": "The pharmaceutical company benefitted from a clutch of analyst price-target raises. These followed Lilly's well-received earnings report.",
    "url": "https://www.fool.com/investing/2023/04/28/why-eli-lilly-stock-was-a-winner-today/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-28T18:11:00-04:00",
    "date_et": "2023-04-28"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-04-30 09:00:01",
    "publisher": "CNBC",
    "title": "Alzheimer's patients may wait years to get treated with new drugs, putting them at risk of more severe disease",
    "image": "https://images.financialmodelingprep.com/news/alzheimers-patients-may-wait-years-to-get-treated-with-20230430.jpeg",
    "site": "cnbc.com",
    "text": "Patients could face wait times ranging from 18 months to four years or more to get diagnosed and then treated for Alzheimer's disease.",
    "url": "https://www.cnbc.com/2023/04/30/alzheimers-treatment-patients-may-wait-years-for-new-drugs.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-04-30T09:00:01-04:00",
    "date_et": "2023-04-30"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-01 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis",
    "image": "https://images.financialmodelingprep.com/news/up-to-73-of-atopic-dermatitis-patients-taking-lillys-20230501.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab's stable and long-lasting results at one year of treatment in patients with moderate-to-severe atopic dermatitis (AD), commonly called eczema.",
    "url": "https://www.prnewswire.com/news-releases/up-to-73-of-atopic-dermatitis-patients-taking-lillys-lebrikizumab-had-improved-or-cleared-skin-on-face-or-hands-in-new-analysis-301811624.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-01T06:45:00-04:00",
    "date_et": "2023-05-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-01 13:02:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Declares Second-Quarter 2023 Dividend",
    "image": "https://images.financialmodelingprep.com/news/lilly-declares-secondquarter-2023-dividend-20230501.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on June 9, 2023 to shareholders of record at the close of business on May 15, 2023.",
    "url": "https://www.prnewswire.com/news-releases/lilly-declares-second-quarter-2023-dividend-301812100.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-01T13:02:00-04:00",
    "date_et": "2023-05-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-01 16:51:05",
    "publisher": "Seeking Alpha",
    "title": "V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023",
    "image": "https://images.financialmodelingprep.com/news/vm-breakouts-top-longterm-growth-and-dividend-stocks-for-20230501.jpg",
    "site": "seekingalpha.com",
    "text": "The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-year returns.",
    "url": "https://seekingalpha.com/article/4598612-v-and-m-breakouts-top-long-term-growth-and-dividend-stocks-for-may-2023",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-01T16:51:05-04:00",
    "date_et": "2023-05-01"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-02 09:45:00",
    "publisher": "The Motley Fool",
    "title": "Is Eli Lilly a Smart Dividend Stock to Buy Now?",
    "image": "https://images.financialmodelingprep.com/news/is-eli-lilly-a-smart-dividend-stock-to-buy-20230502.jpg",
    "site": "fool.com",
    "text": "Eli Lilly is facing stiff but short-term headwinds to its earnings. Its dividend isn't in any danger, and it'll likely continue to rise -- and quickly.",
    "url": "https://www.fool.com/investing/2023/05/02/is-eli-lilly-a-smart-dividend-stock-to-buy-now/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-02T09:45:00-04:00",
    "date_et": "2023-05-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-02 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana",
    "image": "https://images.financialmodelingprep.com/news/lilly-provides-500000-in-grants-to-support-equitable-access-20230502.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 2, 2023 /PRNewswire/ -- To remove barriers and create more equitable, affordable post-high school education opportunities for Indiana's growing immigrant population, Eli Lilly and Company (NYSE: LLY) today announced grants totaling $500,000 to four local nonprofits that offer education assistance to Deferred Action for Childhood Arrivals (DACA) recipients, also known as Dreamers. Currently, Indiana is one of only two states that does not offer DACA eligible students living in Indiana in-state tuition to its state-run colleges and universities.",
    "url": "https://www.prnewswire.com/news-releases/lilly-provides-500-000-in-grants-to-support-equitable-access-to-education-for-dreamers-in-indiana-301813203.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-02T10:00:00-04:00",
    "date_et": "2023-05-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-02 13:12:16",
    "publisher": "MarketBeat",
    "title": "Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding",
    "image": "https://images.financialmodelingprep.com/news/canfite-biopharma-spikes-on-pancreatic-cancer-inhibition-finding-20230502.jpg",
    "site": "marketbeat.com",
    "text": "Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.",
    "url": "https://www.marketbeat.com/originals/can-fite-biopharma-spikes-on-pancreatic-cancer-inhibition-finding/?SNAPI",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-02T13:12:16-04:00",
    "date_et": "2023-05-02"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 06:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease",
    "image": "https://images.financialmodelingprep.com/news/lillys-donanemab-significantly-slowed-cognitive-and-functional-decline-in-20230503.jpg",
    "site": "prnewswire.com",
    "text": "Nearly half (47%) of the participants on donanemab (compared to 29% on placebo) had no clinical progression at 1 year (defined as no decline in CDR-SB) Phase 3 trial met primary endpoint and all secondary endpoints measuring cognitive and functional decline Donanemab treatment slowed clinical decline by 35% compared to placebo, and resulted in 40% less decline on the ability to perform activities of daily living Over half of all participants completed their course of treatment by 12 months  INDIANAPOLIS , May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale (iADRS).",
    "url": "https://www.prnewswire.com/news-releases/lillys-donanemab-significantly-slowed-cognitive-and-functional-decline-in-phase-3-study-of-early-alzheimers-disease-301814001.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T06:00:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 06:00:01",
    "publisher": "CNBC",
    "title": "Eli Lilly Alzheimer's treatment donanemab slowed disease progression in clinical trial",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-alzheimers-treatment-donanemab-slowed-disease-progression-in-20230503.jpeg",
    "site": "cnbc.com",
    "text": "Donanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.",
    "url": "https://www.cnbc.com/2023/05/03/alzheimers-eli-lilly-treatment-donanemab-slowed-disease-progression.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T06:00:01-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 06:00:58",
    "publisher": "InvestorPlace",
    "title": "3 Stocks Quietly Hitting All-Time Highs (and Can Continue Higher)",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-quietly-hitting-alltime-highs-and-can-continue-20230503.png",
    "site": "investorplace.com",
    "text": "It's been a tough 12 to 18 months for investors. The market roared higher into the end of 2021, stumbled big time in 2022, and had a strong start to 2023.",
    "url": "https://investorplace.com/2023/05/3-stocks-quietly-hitting-all-time-highs-and-can-continue-higher/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T06:00:58-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 06:14:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly stock jumps 4% premarket on news of positive results in late-stage trial of Alzheimer's disease treatment",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-jumps-4-premarket-on-news-of-20230503.jpg",
    "site": "marketwatch.com",
    "text": "Eli Lilly & Co.'s stock LLY jumped 4% premarket Wednesday, after the company announced positive data from a late-stage trial of its Alzheimer's disease treatment donanemab. The company said the Phase 3 trial showed that donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer's disease, and met its primary and all secondary endpoints.",
    "url": "https://www.marketwatch.com/story/eli-lilly-stock-jumps-4-premarket-on-news-of-positive-results-in-late-stage-trial-of-alzheimers-disease-treatment-a2a4dc7c",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T06:14:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 06:34:00",
    "publisher": "Barron's",
    "title": "Eli Lilly Stock Jumps on Positive Alzheimer's Drug Phase 3 Trial Data",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-jumps-on-positive-alzheimers-drug-phase-3-20230503.jpg",
    "site": "barrons.com",
    "text": "The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer's disease.",
    "url": "https://www.barrons.com/articles/eli-lilly-stock-alzheimers-drug-a9462788",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T06:34:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 07:48:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly jumps upon Alzheimer trial results, AMD, Starbucks and Ford drop after earnings, and other stocks on the move",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-jumps-upon-alzheimer-trial-results-amd-starbucks-20230503.jpg",
    "site": "marketwatch.com",
    "text": "Livent Corp. shares LTHM jumped nearly 10% premarket Wednesday after the lithium miner posted first-quarter results that topped Wall Street views and raised guidance.",
    "url": "https://www.marketwatch.com/story/eli-lilly-jumps-upon-alzheimer-trial-results-amd-starbucks-and-ford-drop-after-earnings-and-other-stocks-on-the-move-8fcefe0c",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T07:48:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 08:37:00",
    "publisher": "Market Watch",
    "title": "U.S. stock futures inch higher as traders await Fed decision",
    "image": "https://images.financialmodelingprep.com/news/us-stock-futures-inch-higher-as-traders-await-fed-20230503.jpg",
    "site": "marketwatch.com",
    "text": "U.S. stock index futures on Wednesday were recovering a portion of the previous session's sharp selloff, as the focus turns to the Federal Reserve interest rate decision later in the day, while private-sector employment in April increased more than expected.",
    "url": "https://www.marketwatch.com/story/stock-futures-inch-higher-as-traders-await-fed-decision-ac1ab2eb",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T08:37:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 08:46:05",
    "publisher": "The Motley Fool",
    "title": "Good News for Patients Is Lifting These 2 Biopharma Stocks",
    "image": "https://images.financialmodelingprep.com/news/good-news-for-patients-is-lifting-these-2-biopharma-20230503.jpg",
    "site": "fool.com",
    "text": "Markets were waiting to see what the Federal Reserve will do with interest rates later today. Eli Lilly announced favorable trial results for its Alzheimer's treatment.",
    "url": "https://www.fool.com/investing/2023/05/03/good-news-for-patients-lifting-2-biopharma-stocks/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T08:46:05-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 09:16:56",
    "publisher": "Investor's Business Daily",
    "title": "Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-surges-after-alzheimers-treatment-succeeds-biogen-also-20230503.jpg",
    "site": "investors.com",
    "text": "Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline. The post Eli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also Rises appeared first on Investor's Business Daily.",
    "url": "https://www.investors.com/news/technology/eli-lilly-stock-surges-after-alzheimers-treatment-succeeds-in-final-phase-study/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T09:16:56-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 09:44:52",
    "publisher": "InvestorPlace",
    "title": "LLY Stock Alert: Eli Lilly Announces Positive Alzheimer's Drug Data",
    "image": "https://images.financialmodelingprep.com/news/lly-stock-alert-eli-lilly-announces-positive-alzheimers-drug-20230503.jpg",
    "site": "investorplace.com",
    "text": "Eli Lilly (NYSE: LLY ) stock is getting a boost on Wednesday after the company announced results from an Alzheimer's clinical trial. The big news traders are celebrating is the effectiveness of donanemab as a treatment for Alzheimer's.",
    "url": "https://investorplace.com/2023/05/lly-stock-alert-eli-lilly-announces-positive-alzheimers-drug-data/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T09:44:52-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly to Participate in Bank of America Securities 2023 Healthcare Conference",
    "image": "https://images.financialmodelingprep.com/news/lilly-to-participate-in-bank-of-america-securities-2023-20230503.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Securities 2023 Healthcare Conference, May 9-11, 2023. Patrik Jonsson, executive vice president, president of Lilly Immunology and Lilly USA, and chief customer officer, will participate in a fireside chat on Wednesday, May 10 at 1 p.m.",
    "url": "https://www.prnewswire.com/news-releases/lilly-to-participate-in-bank-of-america-securities-2023-healthcare-conference-301813652.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T10:00:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 10:16:00",
    "publisher": "The Wall Street Journal",
    "title": "Eli Lilly's Results Signal Arrival of Blockbuster New Drug Class",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-results-signal-arrival-of-blockbuster-new-drug-20230503.jpg",
    "site": "wsj.com",
    "text": "The company's Alzheimer's drug results might look better than Biogen's, but both makers will likely benefit.",
    "url": "https://www.wsj.com/articles/eli-lillys-results-signal-arrival-of-blockbuster-new-drug-class-bf7802cd",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T10:16:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 10:59:18",
    "publisher": "Schaeffers Research",
    "title": "Biogen Stock Hits Fresh High on Eli Lilly Buzz",
    "image": "https://images.financialmodelingprep.com/news/biogen-stock-hits-fresh-high-on-eli-lilly-buzz-20230503.jpg",
    "site": "schaeffersresearch.com",
    "text": "The shares of Biogen Inc (NASDAQ:BIIB) are enjoying tailwinds from positive news surrounding sector peer Eli Lilly's (LLY) Alzheimer's drug  donanemab.",
    "url": "https://www.schaeffersresearch.com/content/news/2023/05/03/biogen-stock-hits-fresh-high-on-eli-lilly-buzz",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T10:59:18-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 12:55:17",
    "publisher": "Zacks Investment Research",
    "title": "SNY or LLY: Which Is the Better Value Stock Right Now?",
    "image": "https://images.financialmodelingprep.com/news/sny-or-lly-which-is-the-better-value-stock-right-20230503.jpg",
    "site": "zacks.com",
    "text": "Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Sanofi (SNY) or Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?",
    "url": "https://www.zacks.com/stock/news/2089192/sny-or-lly-which-is-the-better-value-stock-right-now",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T12:55:17-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 13:59:00",
    "publisher": "The Motley Fool",
    "title": "Why Eli Lilly Stock Is Bolting Higher Today",
    "image": "https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-bolting-higher-today-20230503.jpg",
    "site": "fool.com",
    "text": "Eli Lilly announced better-than-expected trial results for its early-stage Alzheimer's disease candidate, donanemab, today. The drug's latest results paint an encouraging picture for patients.",
    "url": "https://www.fool.com/investing/2023/05/03/why-eli-lilly-stock-is-bolting-higher-today/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T13:59:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-03 14:07:00",
    "publisher": "Market Watch",
    "title": "Eli Lilly's positive results from a Alzheimer's trial seen as ‘potentially very important'",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-positive-results-from-a-alzheimers-trial-seen-20230503.jpg",
    "site": "marketwatch.com",
    "text": "Positive results from an Alzheimer's trial by Eli Lilly are seen as a very important step in the battle to fight the fatal disease, but questions remain about whether it will be covered by Medicare.",
    "url": "https://www.marketwatch.com/story/eli-lillys-positive-results-from-a-alzheimers-trial-seen-as-potentially-very-important-53e008a1",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-03T14:07:00-04:00",
    "date_et": "2023-05-03"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 05:13:00",
    "publisher": "The Motley Fool",
    "title": "Should You Buy Eli Lilly Stock Now?",
    "image": "https://images.financialmodelingprep.com/news/should-you-buy-eli-lilly-stock-now-20230504.jpg",
    "site": "fool.com",
    "text": "Eli Lilly announced the successful results of a phase 3 trial with donanemab, an experimental treatment for Alzheimer's disease. Treatment with the Alzheimer's disease candidate appeared to reduce the rate of cognitive decline even better than another drug called Leqembi from Eisai and Biogen.",
    "url": "https://www.fool.com/investing/2023/05/04/should-you-buy-eli-lilly-stock-now/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T05:13:00-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 05:57:00",
    "publisher": "The Motley Fool",
    "title": "These Have Been 3 of the Best-Performing Healthcare Stocks Since 2020",
    "image": "https://images.financialmodelingprep.com/news/these-have-been-3-of-the-bestperforming-healthcare-stocks-20230504.jpg",
    "site": "fool.com",
    "text": "Demand for Moderna's COVID-19 vaccine will taper off this year, but investors remain bullish on its prospects. McKesson is a top distributor of pharmaceuticals and a key cog in the healthcare industry.",
    "url": "https://www.fool.com/investing/2023/05/04/best-performing-healthcare-stocks-since-2020/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T05:57:00-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 09:23:00",
    "publisher": "The Motley Fool",
    "title": "Here's the Best Reason to Buy Eli Lilly Stock Right Now",
    "image": "https://images.financialmodelingprep.com/news/heres-the-best-reason-to-buy-eli-lilly-stock-20230504.jpg",
    "site": "fool.com",
    "text": "The pharmaceutical giant's first-quarter results were hardly impressive. But the company's drug Mounjaro recently reported an important clinical win.",
    "url": "https://www.fool.com/investing/2023/05/04/heres-the-best-reason-to-buy-eli-lilly-stock-right/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T09:23:00-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 10:15:00",
    "publisher": "The Motley Fool",
    "title": "Should Investors Buy This Hot Growth Stock?",
    "image": "https://images.financialmodelingprep.com/news/should-investors-buy-this-hot-growth-stock-20230504.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's financial results were challenged by a recent decision from the FDA. The stock's dividend payout is modest but positioned to grow robustly.",
    "url": "https://www.fool.com/investing/2023/05/04/should-investors-buy-this-hot-growth-stock/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T10:15:00-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 10:41:32",
    "publisher": "Zacks Investment Research",
    "title": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-attracting-investor-attention-20230504.jpg",
    "site": "zacks.com",
    "text": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://www.zacks.com/stock/news/2089908/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T10:41:32-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 10:55:34",
    "publisher": "Seeking Alpha",
    "title": "Eli Lilly's Alzheimer's Breakthrough: A Game Changer For Investors And Patients",
    "image": "https://images.financialmodelingprep.com/news/eli-lillys-alzheimers-breakthrough-a-game-changer-for-investors-20230504.jpg",
    "site": "seekingalpha.com",
    "text": "Eli Lilly's donanemab shows promise in slowing Alzheimer's progression, offering significant market potential. Competitive landscape between Eli Lilly, Eisai, and Biogen could drive further innovation in Alzheimer's therapies.",
    "url": "https://seekingalpha.com/article/4599880-eli-lilly-alzheimers-breakthrough-game-changer-investors-patients",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T10:55:34-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-04 15:29:16",
    "publisher": "InvestorPlace",
    "title": "Which Healthcare Stock Is a Compelling Pick for the Long Haul?",
    "image": "https://images.financialmodelingprep.com/news/which-healthcare-stock-is-a-compelling-pick-for-the-20230504.jpg",
    "site": "investorplace.com",
    "text": "Investors remain puzzled due to persistent macro challenges, continued interest rate hikes, and the regional banking crisis. Given the ongoing uncertainties, sectors that are resilient during economic downturns could offer attractive investment opportunities.",
    "url": "https://investorplace.com/2023/05/which-healthcare-stock-is-a-compelling-pick-for-the-long-haul/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-04T15:29:16-04:00",
    "date_et": "2023-05-04"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-05 07:00:08",
    "publisher": "Investor's Business Daily",
    "title": "This Top Fund Manager Buys Growth Stocks Without Paying Too Much",
    "image": "https://images.financialmodelingprep.com/news/this-top-fund-manager-buys-growth-stocks-without-paying-20230505.jpg",
    "site": "investors.com",
    "text": "Daniel Morris, manager of top mutual fund Manor Growth Fund (MNRGX), admits he has a conservative streak. The post This Top Fund Manager Buys Growth Stocks Without Paying Too Much appeared first on Investor's Business Daily.",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/top-mutual-fund-manager-buys-growth-without-paying-up/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-05T07:00:08-04:00",
    "date_et": "2023-05-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-05 10:15:00",
    "publisher": "The Motley Fool",
    "title": "Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?",
    "image": "https://images.financialmodelingprep.com/news/which-is-the-better-passive-income-stock-eli-lilly-20230505.jpg",
    "site": "fool.com",
    "text": "There are often trade-offs to make when selecting passive income stocks. Eli Lilly's next couple of years will see its revenue burgeon by billions.",
    "url": "https://www.fool.com/investing/2023/05/05/which-is-the-better-passive-income-stock-eli-lilly/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-05T10:15:00-04:00",
    "date_et": "2023-05-05"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-06 07:55:00",
    "publisher": "The Motley Fool",
    "title": "2 Best Biotech Stocks to Buy Right Now",
    "image": "https://images.financialmodelingprep.com/news/2-best-biotech-stocks-to-buy-right-now-20230506.jpg",
    "site": "fool.com",
    "text": "Eli Lilly and Amgen both boast exceptional product portfolios and pipelines. The two companies pay growing dividends to shareholders.",
    "url": "https://www.fool.com/investing/2023/05/06/best-biotech-stocks-to-buy-right-now/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-06T07:55:00-04:00",
    "date_et": "2023-05-06"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-07 08:14:00",
    "publisher": "The Motley Fool",
    "title": "2 Top Healthcare Stocks Defying the Bear Market",
    "image": "https://images.financialmodelingprep.com/news/2-top-healthcare-stocks-defying-the-bear-market-20230507.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's tirzepatide could be a weight-loss blockbuster. Merck continues to add indications for oncology therapy Keytruda.",
    "url": "https://www.fool.com/investing/2023/05/07/2-top-healthcare-stocks-defying-the-bear-market/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-07T08:14:00-04:00",
    "date_et": "2023-05-07"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-08 05:05:00",
    "publisher": "The Motley Fool",
    "title": "3 Things About Eli Lilly That Smart Investors Know",
    "image": "https://images.financialmodelingprep.com/news/3-things-about-eli-lilly-that-smart-investors-know-20230508.jpg",
    "site": "fool.com",
    "text": "The next couple of years will see Eli Lilly's top and bottom lines swell. Its debt load looks like more of a problem than it actually is.",
    "url": "https://www.fool.com/investing/2023/05/08/3-things-about-eli-lilly-that-smart-investors-know/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-08T05:05:00-04:00",
    "date_et": "2023-05-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-08 05:57:00",
    "publisher": "The Motley Fool",
    "title": "Where Will Eli Lilly Be in 3 Years?",
    "image": "https://images.financialmodelingprep.com/news/where-will-eli-lilly-be-in-3-years-20230508.jpg",
    "site": "fool.com",
    "text": "Eli Lilly's near-term outlook is quite favorable. The only major constraint it faces is competition in several drug markets.",
    "url": "https://www.fool.com/investing/2023/05/08/where-will-eli-lilly-be-in-3-years/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-08T05:57:00-04:00",
    "date_et": "2023-05-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-08 10:56:49",
    "publisher": "The Motley Fool",
    "title": "Why Did Eli Lilly Stock Jump 15% in April?",
    "image": "https://images.financialmodelingprep.com/news/why-did-eli-lilly-stock-jump-15-in-april-20230508.jpg",
    "site": "fool.com",
    "text": "Eli Lilly published positive clinical trial results on a weight-loss drug and an early-stage Alzheimer's treatment candidate. Though its Q1 results fell short of analysts' estimates, investors were pleased with management's updated 2023 forecast.",
    "url": "https://www.fool.com/investing/2023/05/08/why-did-eli-lilly-stock-jump-15-in-april/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-08T10:56:49-04:00",
    "date_et": "2023-05-08"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-09 06:45:00",
    "publisher": "PRNewsWire",
    "title": "Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis",
    "image": "https://images.financialmodelingprep.com/news/lilly-discloses-firstinclass-interim-phase-2-data-in-pediatric-20230509.jpg",
    "site": "prnewswire.com",
    "text": "- First interim Phase 2 data of an IL-23p19 antagonist in pediatric patients - New analysis from the pivotal Phase 3 LUCENT-1 and LUCENT-2 studies INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today new investigational data for mirikizumab in patients with moderately to severely active ulcerative colitis (UC) that further support the efficacy and safety seen in previous pivotal studies.  Data presented at Digestive Disease Week® (DDW), held in Chicago from May 6-9, include an oral presentation of an interim analysis of mirikizumab as induction therapy in pediatric patients with moderately to severely active UC from the Phase 2 SHINE-1 study, and a new analysis from LUCENT-1 and LUCENT-2 studies evaluating the relative association of bowel urgency remission on Inflammatory Bowel Disease Questionnaire (IBDQ) scores, which assess the impact of UC on quality of life in adults.",
    "url": "https://www.prnewswire.com/news-releases/lilly-discloses-first-in-class-interim-phase-2-data-in-pediatric-patients-and-new-analysis-from-phase-3-program-in-adult-patients-for-mirikizumab-in-ulcerative-colitis-301818874.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-09T06:45:00-04:00",
    "date_et": "2023-05-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-09 06:45:43",
    "publisher": "InvestorPlace",
    "title": "3 Dividend Stocks to Buy as the Healthcare Sector Booms in 2023",
    "image": "https://images.financialmodelingprep.com/news/3-dividend-stocks-to-buy-as-the-healthcare-sector-20230509.jpg",
    "site": "investorplace.com",
    "text": "After a relatively impressive 2022, the best healthcare dividend stocks have hit a temporary rough patch this year. However, savvy investors shouldn't let this blip deter them from wagering on this defensive sector for income stock opportunities.",
    "url": "https://investorplace.com/2023/05/3-dividend-stocks-to-buy-as-the-healthcare-sector-booms-in-2023/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-09T06:45:43-04:00",
    "date_et": "2023-05-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-09 09:00:00",
    "publisher": "PRNewsWire",
    "title": "Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation",
    "image": "https://images.financialmodelingprep.com/news/lillys-social-impact-venture-capital-portfolio-poised-to-grow-20230509.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company's commitment to going beyond the medicines it makes to have a positive impact on patients and society through for-profit investments. The portfolio is aligned with Lilly's efforts to combat racial injustice and its effects on Black Americans and historically marginalized communities in the U.S., as well as Lilly 30x30, a global initiative to improve access to quality healthcare for 30 million people living in limited-resource settings annually by 2030.",
    "url": "https://www.prnewswire.com/news-releases/lillys-social-impact-venture-capital-portfolio-poised-to-grow-to-300-million-with-new-50-million-allocation-301818785.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-09T09:00:00-04:00",
    "date_et": "2023-05-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-09 20:00:00",
    "publisher": "PRNewsWire",
    "title": "The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy",
    "image": "https://images.financialmodelingprep.com/news/the-china-nmpa-approves-tyvyt-sintilimab-injection-in-combination-20230509.jpg",
    "site": "prnewswire.com",
    "text": "ROCKVILLIE, Md. and SUZHOU, China, May 9, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (\"Innovent\") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company (\"Lilly\", NYSE: LLY), jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) in combination with bevacizumab and chemotherapy (pemetrexed and cisplatin) in patients with epidermal growth factor receptor (EGFR)-mutated non-squamous non-small cell lung cancer (NSCLC) who progressed after EGFR tyrosine kinase inhibitor (TKI) therapy.",
    "url": "https://www.prnewswire.com/news-releases/the-china-nmpa-approves-tyvyt-sintilimab-injection-in-combination-with-bevacizumab-and-chemotherapy-in-patients-with-egfr-mutated-non-squamous-nsclc-who-progressed-after-egfr-tki-therapy-301819664.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-09T20:00:00-04:00",
    "date_et": "2023-05-09"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-10 14:27:03",
    "publisher": "Zacks Investment Research",
    "title": "Bearish Headwinds Have Evolved to Bullish Tailwinds: This Industry Soars",
    "image": "https://images.financialmodelingprep.com/news/bearish-headwinds-have-evolved-to-bullish-tailwinds-this-industry-20230510.jpg",
    "site": "zacks.com",
    "text": "The headline inflation figure rose at the slowest rate in more than two years.",
    "url": "https://www.zacks.com/commentary/2093698/bearish-headwinds-have-evolved-to-bullish-tailwinds-this-industry-soars",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-10T14:27:03-04:00",
    "date_et": "2023-05-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-10 17:37:58",
    "publisher": "CNBC",
    "title": "Eli Lilly CEO vows not to raise insulin prices again, while Novo Nordisk and Sanofi hedge",
    "image": "https://images.financialmodelingprep.com/news/eli-lilly-ceo-vows-not-to-raise-insulin-prices-20230510.jpeg",
    "site": "cnbc.com",
    "text": "He was the only executive to do so before a Senate Health Committee hearing that also included the CEOs of Novo Nordisk and Sanofi.",
    "url": "https://www.cnbc.com/2023/05/10/eli-lilly-novo-nordisk-sanofi-ceos-on-insulin-prices.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-10T17:37:58-04:00",
    "date_et": "2023-05-10"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-11 10:00:00",
    "publisher": "PRNewsWire",
    "title": "Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting",
    "image": "https://images.financialmodelingprep.com/news/loxolilly-announces-details-of-presentations-at-2023-european-hematology-20230511.jpg",
    "site": "prnewswire.com",
    "text": "INDIANAPOLIS , May 11, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually. The company-sponsored abstracts include new analyses of clinical data in approved and investigational uses based on the BRUIN Phase 1/2 trial evaluating Jaypirca™ (pirtobrutinib) in patients with B-cell malignancies previously treated with a covalent Bruton's tyrosine kinase (BTK) inhibitor, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).",
    "url": "https://www.prnewswire.com/news-releases/loxolilly-announces-details-of-presentations-at-2023-european-hematology-association-eha-annual-meeting-301821102.html",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-11T10:00:00-04:00",
    "date_et": "2023-05-11"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-11 10:07:00",
    "publisher": "The Motley Fool",
    "title": "Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal",
    "image": "https://images.financialmodelingprep.com/news/heres-why-eli-lillys-alzheimers-drug-could-be-the-20230511.jpg",
    "site": "fool.com",
    "text": "Trial data show that donanemab may potentially slow the progression of Alzheimer's. The drug candidate has also been effective in reducing amyloid plaque in the brain.",
    "url": "https://www.fool.com/investing/2023/05/11/heres-why-eli-lillys-alzheimers-drug-could-be-the/",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-11T10:07:00-04:00",
    "date_et": "2023-05-11"
  },
  {
    "symbol": "LLY",
    "publishedDate": "2023-05-11 14:46:00",
    "publisher": "Market Watch",
    "title": "Prescription-drug costs in spotlight as pharmacy benefit reform advances in Senate",
    "image": "https://images.financialmodelingprep.com/news/prescriptiondrug-costs-in-spotlight-as-pharmacy-benefit-reform-advances-20230511.jpg",
    "site": "marketwatch.com",
    "text": "A bipartisan effort to rein in prescription drug prices advanced Thursday as a key U.S. Senate committee approved a bill aimed at reforming pharmacy benefit managers.",
    "url": "https://www.marketwatch.com/story/prescription-drug-costs-in-spotlight-as-pharmacy-benefit-reform-advances-in-senate-ae6eb47d",
    "ticker": "LLY",
    "event_date": "2023-04-27",
    "window_start": "2023-04-13",
    "window_end": "2023-05-11",
    "publishedDateET": "2023-05-11T14:46:00-04:00",
    "date_et": "2023-05-11"
  }
]